Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 4/2022

01-04-2022 | Care | Original Paper

Injection and Non-Injection Drug Use Among Adults with Diagnosed HIV in the United States, 2015–2018

Authors: Kathleen Wu, Yunfeng Tie, Sharoda Dasgupta, Linda Beer, Ruthanne Marcus

Published in: AIDS and Behavior | Issue 4/2022

Login to get access

Abstract

Understanding behavioral characteristics and health outcomes of people with HIV (PWH) who inject drugs and PWH who use drugs, but do not inject, can help inform public health interventions and improve HIV clinical outcomes. However, recent, nationally representative estimates are lacking. We used 2015–2018 Medical Monitoring Project data to examine health outcome differences among adults with diagnosed HIV who injected drugs or who only used non-injection drugs in the past year. Data were obtained from participant interviews and medical record abstraction. We reported weighted percentages and prevalence ratios with predicted marginal means to assess differences between groups (P < 0.05). PWH who injected drugs were more likely to engage in high-risk sex; experience depression and anxiety symptoms, homelessness, and incarceration; and have lower levels of care retention, antiretroviral therapy adherence, and viral suppression. Tailored, comprehensive interventions are critical for improving outcomes among PWH who use drugs, particularly among those who inject drugs.
Literature
1.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.PubMedPubMedCentralCrossRef
2.
Ladak F, Socias E, Nolan S, et al. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a canadian setting. Antivir Ther. 2019;24(1):19–25.PubMedPubMedCentralCrossRef
3.
Nolan S, Walley AY, Heeren TC, et al. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017;29(9):1129–36.PubMedPubMedCentralCrossRef
4.
Marta V, Hayk D, Olga D, et al. Anxiety, depression, and quality of life among HIV positive injection drug users in Ukraine, 2017. J Infect Dev Ctries. 2019;13:111S–7S.CrossRef
5.
Beer L, Tie Y, Padilla M. Shouse RL for the Medical Monitoring Project. Generalized anxiety disorder symptoms among persons with diagnosed HIV in the United States—2015–2016, Medical Monitoring Project. AIDS. 2019;33(11):1781–7.PubMedCrossRef
6.
Earnshaw V, Smith L, Copenhaver M. Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Health Addiction. 2013;11(1):110–22.CrossRef
7.
8.
Aidala AA, Wilson MG, Shubert V, et al. Housing status, medical care, and health outcomes among people living with HIV/AIDS: a systematic review. Am J Public Health. 2016;106(1):e1–23.PubMedPubMedCentralCrossRef
9.
Altice FL, Azbel L, Stone J, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis c virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228–48.PubMedPubMedCentralCrossRef
10.
Hodder SL, Feinberg J, Strathdee SA, et al. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021;397:1139–50.PubMedCrossRef
11.
Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence - North Carolina, 2010–2015. Morb Mortal Wkly Rep. 2017;66(22):569–73.CrossRef
12.
Visconti AJ, Sell J, Greenblatt AD. Primary care for persons who inject drugs. Am Fam Physician. 2019;99(2):109–16.PubMed
13.
Collier MG, Doshani M, Asher A. Using population based hospitalization data to monitor increases in conditions causing morbidity among persons who inject drugs. J Community Health. 2018;43(3):598–603.PubMedCrossRef
14.
Jenkins LM, Banta-Green CJ, Maynard C, et al. Risk factors for nonfatal overdose at Seattle-area syringe exchanges. J Urban Health. 2011;88(1):118–28.PubMedPubMedCentralCrossRef
15.
Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207.PubMedPubMedCentralCrossRef
16.
Dasgupta S, Tie Y, Lemons A, Wu K, Burnett J, RL S. . Injection practices and sexual behaviors among persons with diagnosed HIV infection who inject drugs — United States, 2015–2017. Morb Mortal Wkly Rep. 2019;68:653–7.CrossRef
17.
Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309–17.PubMedPubMedCentralCrossRef
18.
Kuchinad KE, Hutton HE, Monroe AK, Anderson G, Moore RD, Chander G. A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse. BMC Res Notes. 2016;9:229.PubMedPubMedCentralCrossRef
19.
Rosen MI, Black AC, Arnsten JH, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–7.PubMedPubMedCentralCrossRef
20.
Celentano DD, Latimore AD, Mehta SH. Variations in sexual risks in drug users: emerging themes in a behavioral context. Curr HIV/AIDS Rep. 2008;5(4):212–8.PubMedPubMedCentralCrossRef
21.
Broz D, Wejnert C, Pham HT, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users — National HIV Behavioral Surveillance System, 20 US Cities, 2009. Morb Mortal Wkly Rep. 2014;63(6):1–51.
22.
Adams M, An Q, Broz D, Burnett J, Wejnert C, Paz-Bailey G. Distributive syringe sharing and use of syringe services programs (SSPs) among persons who inject drugs. AIDS Behav. 2019;23:3306–14.PubMedCrossRef
23.
Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research network of integrated clinical systems cohort. Am J Public Health. 2013;103(8):1457–67.PubMedPubMedCentralCrossRef
24.
Metsch LR, Pereyra M, Purcell DW, et al. Correlates of lending needles/syringes among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46(Suppl 2):S72–9.PubMedCrossRef
25.
Lyss SB, Buchacz K, McClung RP, Asher A, Oster AM. Responding to outbreaks of human immunodeficiency virus among persons who inject drugs-United States, 2016–2019: Perspectives on recent experience and lessons learned. J Infect Dis. 2020;222(5):S239–49.PubMedCrossRef
26.
Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39.PubMedCrossRef
27.
Cranston K, Alpren C, John B, et al. Notes from the field: HIV diagnoses among persons who inject drugs – Northeastern Massachusetts, 2015–2018. Morb Mortal Wkly Rep. 2019;68:253–4.CrossRef
28.
Golden M, Lechtenberg R, Glick S, et al. Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs - Seattle, Washington, 2018. Morb Mortal Wkly Rep. 2019;68(15):344–9.CrossRef
29.
Strathdee SA, Beyrer C. Threading the needle - how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373(5):397–9.PubMedCrossRef
30.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5.PubMedCrossRef
31.
U.S. Department of Health and Human Services. HIV national strategic plan for the United States: a roadmap to end the epidemic 2021–2025. Washington, DC.
32.
Beer L, Johnson CH, Fagan JL, et al. A national behavioral and clinical surveillance system of adults with diagnosed HIV (the Medical Monitoring Project): protocol for an annual cross-sectional interview and medical record abstraction survey. JMIR Res Protoc. 2019;8(11):15453.CrossRef
33.
34.
Mannes ZL, Burrell LE 2nd, Ferguson EG, et al. The association of therapeutic versus recreational marijuana use and antiretroviral adherence among adults living with HIV in Florida. Patient Prefer Adherence. 2018;12:1363–72.PubMedPubMedCentralCrossRef
35.
Montgomery L, Bagot K, Brown JL, Haeny AM. The association between marijuana use and HIV continuum of care outcomes: a systematic review. Curr HIV/AIDS Rep. 2019;16(1):17–28.PubMedPubMedCentralCrossRef
36.
37.
Thrasher AD, Earp JAL, Golin CE, Zimmer CR. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. 2008;49(1):84–93.
38.
Schuster MA, Collins R, Cunningham WE, et al. Perceived discrimination in clinical care in a nationally representative sample of HIV-infected adults receiving health care. J Gen Intern Med. 2005;20(9):807–13.PubMedPubMedCentralCrossRef
39.
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the gad-7. JAMA Intern Med. 2006;166(10):1092–7.CrossRef
40.
Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1):163–73.PubMedCrossRef
41.
Centers for Disease Control and Prevention (2020) Behavioral and clinical characteristics of persons with diagnosed HIV infection—Medical Monitoring Project, United States, 2018 cycle (June 2018–May 2019).
42.
Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7(2):99–106.PubMedPubMedCentralCrossRef
43.
Maloney KM, Beer L, Tie Y, Dasgupta S. Prevalence of non-medical amphetamine use among men with diagnosed HIV infection who have sex with men in the United States, 2015–2016. AIDS Behav. 2019;24:1865–75.CrossRef
44.
Massanella M, Gianella S, Schrier R, et al. Methamphetamine use in HIV-infected individuals affects t-cell function and viral outcome during suppressive antiretroviral therapy. Sci Rep. 2015;5(1):13179.PubMedPubMedCentralCrossRef
45.
Purohit V, Rapaka R, Shurtleff D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol. 2011;44(1):102–10.PubMedCrossRef
46.
Gannon BM, Reichard EE, Fantegrossi WE. Psychostimulant abuse and HIV infection: cocaine, methamphetamine, and “bath salts” cathinone analogues. Curr Addict Rep. 2014;1(3):237–42.PubMedPubMedCentralCrossRef
47.
48.
49.
Broz D, Zibbell J, Foote C, et al. Multiple injections per injection episode: high-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana. Int J Drug Policy. 2018;52:97–101.PubMedCrossRef
50.
51.
Patel MR, Foote C, Duwve J, et al. Reduction of injection-related risk behaviors after emergency implementation of a syringe services program during an HIV outbreak. J Acquir Immune Defic Syndr. 2018;77(4):373–82.PubMedCrossRef
52.
Dasgupta S, Broz D, Tanner M, et al. Changes in reported injection behaviors following the public health response to an HIV outbreak among people who inject drugs: Indiana, 2016. AIDS Behav. 2019;23(12):3257–66.PubMedCrossRef
53.
54.
Miller WC, Hoffman IF, Hanscom BS, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018;392(10149):747–59.PubMedPubMedCentralCrossRef
55.
Do AN, Rosenberg ES, Sullivan PS, et al. Excess burden of depression among HIV-infected persons receiving medical care in the United States: data from the Medical Monitoring Project and the Behavioral Risk Factor Surveillance System. PLoS ONE. 2014;9(3):92842.CrossRef
56.
57.
Pence BW, Mills JC, Bengtson AM, et al. Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiat. 2018;75(4):379–85.CrossRef
58.
Wainwright JJ, Beer L, Tie Y, Fagan JL, Dean HD, Medical Monitoring Project. Socioeconomic, behavioral, and clinical characteristics of persons living with HIV who experience homelessness in the United States, 2015–2016. AIDS Behav. 2020;24(6):1701–8.PubMedPubMedCentralCrossRef
59.
Padilla M, Frazier EL, Carree T, Luke Shouse R, Fagan J. Mental health, substance use and HIV risk behaviors among HIV-positive adults who experienced homelessness in the United States – Medical Monitoring Project, 2009–2015. AIDS Care. 2020;32(5):594–9.PubMedCrossRef
60.
Rajabiun S, Tryon J, Feaster M, et al. The influence of housing status on the HIV continuum of care: results from a multisite study of patient navigation models to build a medical home for people living with HIV experiencing homelessness. Am J Public Health. 2018;108(S7):S539–45.PubMedPubMedCentralCrossRef
61.
62.
Kidder D, Wolitski R, Pals S, Campsmith ML. Housing status and HIV risk behaviors among homeless and housed persons with HIV. J Acquir Immune Defic Syndr. 2008;49(4):451–5.PubMedCrossRef
63.
Terzian AS, Irvine MK, Hollod LM, Lim S, Rojas J, Shepard CW. Effect of HIV housing services on engagement in care and treatment, New York City, 2011. AIDS Behav. 2015;19(11):2087–96.PubMedPubMedCentralCrossRef
64.
Padgett D, Henwood B, Tsemberis S (2015) Housing first: ending homelessness, transforming systems, and changing lives: Oxford University Press.
65.
Knowlton AR, Arnsten JH, Eldred LJ, et al. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors. AIDS Patient Care STDS. 2010;24(7):421–8.PubMedPubMedCentralCrossRef
66.
Zelenev A, Marcus R, Kopelev A, et al. Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav. 2013;17(2):181–94.CrossRef
67.
68.
Flanigan TP, Beckwith CG. The intertwined epidemics of HIV infection, incarceration, and substance abuse: a call to action. J Infect Dis. 2011;203(9):1201–3.PubMedCrossRef
69.
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014;174(5):721–9.PubMedPubMedCentralCrossRef
70.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.PubMedPubMedCentralCrossRef
71.
Khan MR, McGinnis KA, Grov C, et al. Past year and prior incarceration and HIV transmission risk among HIV -positive men who have sex with men in the US. AIDS Care. 2019;31(3):349–56.PubMedCrossRef
72.
Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013;26(1):10–6.PubMedPubMedCentralCrossRef
73.
Costa M, Montague BT, Solomon L, et al. Assessing the effect of recent incarceration in prison on HIV care retention and viral suppression in two states. J Urban Health. 2018;95(4):499–507.PubMedPubMedCentralCrossRef
74.
Beckwith CG, Zaller ND, Fu JJ, Montague BT, Rich JD. Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr. 2010;55:S49–55.PubMedPubMedCentralCrossRef
75.
Kral AH, Lambdin BH, Comfort M, et al. A strengths-based case management intervention to reduce HIV viral load among people who use drugs. AIDS Behav. 2018;22(1):146–53.PubMedCrossRef
76.
Claborn K, Becker S, Operario D, Safren S, Rich JD, Ramsey S. Adherence intervention for HIV-infected persons who use drugs: adaptation, open trial, and pilot randomized hybrid type 1 trial protocol. Addict Sci Clin Pract. 2018;13(1):12.PubMedPubMedCentralCrossRef
77.
Wittwer R, Hubrich S. Nonresponse in household surveys: a survey of nonrespondents from the repeated cross-sectional study “Mobility in Cities – SrV” in Germany. Transp Res Proc. 2015;11:66–84.
78.
Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr. 2010;55(2):S84–7.PubMedPubMedCentralCrossRef
79.
Levitt A, Mermin J, Jones CM, See I, Butler JC. Infectious diseases and injection drug use: public health burden and response. J Infect Dis. 2020;222(5):S213–7.PubMedCrossRef
Metadata
Title
Injection and Non-Injection Drug Use Among Adults with Diagnosed HIV in the United States, 2015–2018
Authors
Kathleen Wu
Yunfeng Tie
Sharoda Dasgupta
Linda Beer
Ruthanne Marcus
Publication date
01-04-2022
Publisher
Springer US
Published in
AIDS and Behavior / Issue 4/2022
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03457-9

Other articles of this Issue 4/2022

AIDS and Behavior 4/2022 Go to the issue

Original Paper

Effectiveness of a Combined Motivational Interviewing and Cognitive Behavioral Intervention to Reduce Substance Use and Improve HIV-Related Immune Functioning

Original Paper

PrEP Use and Adherence Among Transgender Patients

Original Paper

Reddit on PrEP: Posts About Pre-exposure Prophylaxis for HIV from Reddit Users, 2014–2019

Original Paper

Correlates and Effects of Alcohol Use Expectancies Among Persons Living with HIV in Uganda

Original Paper

PrEP Use and Correlates of Use Among a Large, Urban Sample of Men and Transgender Persons Who Have Sex with Men

Original Paper

Subjective Cognitive Complaints: Predictors and Health Outcomes in People Living with HIV
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits